Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus
Vir is working to rapidly determine whether its previously identified anti-coronavirus monoclonal antibodies (mAbs) bind and neutralize 2019-nCoV, also referred to as “Wuhan coronavirus”.
“We have a library of multiple fully-human mAbs that bind and neutralize coronaviruses such as SARS and MERS,” said Herbert “Skip” Virgin, M.D., Ph.D., Chief Scientific Officer of Vir. “These mAbs were discovered using our antibody platform that identifies mAbs from survivors of an infection. Some of these mAbs are able to neutralize zoonotic coronaviruses, and we believe may have the potential to treat and prevent
In addition to Vir’s mAb efforts, its scientists are planning to apply whole genome CRISPR-based screening capabilities (Vir’s innate immunity platform) to identify the host receptor that allows
“We appreciate the threat this pathogen presents, and are utilizing our technologies to determine whether we currently have, or can identify, therapies to neutralize this virus,” said
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding plans to apply Vir’s innate immunity platform to identify the host receptor that allows
Vir Biotechnology, Inc.Investors Neera Ravindran, MD Head of Investor Relations & Strategic Communicationsnravindran@vir.bio +1-415-506-5256 Media Lindy DevereuxScient PR email@example.com +1-646-515-5730
Source: Vir Biotechnology, Inc.